Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Berger, J. S.
  • Herout, P. M.
  • Harshaw, Q.
  • Steinhubl, Steven
  • Frye, C. B.
  • Becker, R. C.

publication date

  • July 2012

journal

  • Journal of Thrombosis and Thrombolysis  Journal

abstract

  • Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity. We studied the impact of clopidogrel pre-treatment in patients undergoing off-pump versus on-pump coronary revascularization. This report describes a post hoc analysis of 431 on-pump and 165 off-pump cases from a retrospective multicenter study of the impact of preoperative (within 5 days) clopidogrel use on bleeding related outcomes and surgical reintervention. Logistic regression was used to analyze the outcomes with respect to surgery type and clopidogrel exposure while using a propensity score risk adjustment for off-pump surgery. The hospital length of stay (9.3 ± 5.4 days vs. 8.9 ± 5.3 days, p = 0.35), major bleeding (21% vs. 20%, p = 0.74) and reoperation (3.7% vs. 4.8%, p = 0.53) were similar between on-pump and off-pump, respectively. In both surgical cohorts, recent clopidogrel use was associated with a greater incidence of major bleeding, reoperation, and transfusion. After multivariable adjustment, the odds ratio of major bleeding (1.76, 95% confidence interval 0.88-3.52 on-pump; 2.37, 95% confidence interval 1.06-5.30 off-pump) and reoperation (4.52, 95% confidence interval 0.58-36.6 in on-pump; 7.05, 95% confidence interval 0.82-60.5 in off-pump) was increased in clopidogrel-treated patients compared to no clopidogrel. Major bleeding and reoperation did not differ significantly between patients undergoing on- or off-pump surgery. Clopidogrel treatment within 5 days prior to surgery increased the risk of bleeding and reoperation in all CABG patients irrespective of whether surgery was performed on- or off-pump.

subject areas

  • Acute Coronary Syndrome
  • Aged
  • Coronary Artery Bypass, Off-Pump
  • Female
  • Hemorrhage
  • Humans
  • Length of Stay
  • Logistic Models
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors
  • Preoperative Care
  • Retrospective Studies
  • Risk Factors
  • Ticlopidine
scroll to property group menus

Research

keywords

  • Bleeding
  • CABG: Clopidogrel
  • Off-pump
  • Reoperation
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0929-5305

Digital Object Identifier (DOI)

  • 10.1007/s11239-012-0694-x

PubMed ID

  • 22350624
scroll to property group menus

Additional Document Info

start page

  • 56

end page

  • 64

volume

  • 34

issue

  • 1

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support